Molsidomine Arrow (Molsidomine)

Molsidomine is a prodrug that is converted in the bloodstream to an active metabolite that releases nitric oxide. The nitric oxide activates guanylate cyclase, raising cyclic GMP levels in vascular smooth muscle, which leads to relaxation of the vessels, lowered systemic resistance, and decreased myocardial oxygen consumption.

The appropriate dose of Molsidomine Arrow is determined by the prescribing physician based on the patient’s clinical condition, response to therapy, and any co‑existing medical issues. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for molsidomine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Molsidomine differs from traditional nitrates because it is a nitric‑oxide donor that does not require nitrate‑free intervals, reducing the risk of tolerance. Compared with beta‑blockers or calcium‑channel blockers, it primarily acts by vasodilation rather than heart‑rate reduction, offering an alternative mechanism for patients who cannot tolerate those classes.

Molsidomine Arrow should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, heat, and direct sunlight to maintain potency throughout the shelf life.

Molsidomine Arrow is taken orally with water, usually with or without food as directed by the prescriber. The tablets should be swallowed whole and not chewed or crushed, ensuring consistent absorption of the active ingredient.

The most serious risks include severe hypotension, syncope, and rare allergic reactions such as Stevens‑Johnson syndrome. Patients should be monitored for sudden drops in blood pressure, especially when combined with other vasodilators, and any signs of rash or systemic allergic response should prompt immediate medical evaluation.

Molsidomine is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, and it should be avoided in individuals taking concurrent nitrate therapy due to the risk of profound hypotension. Caution is also advised for patients with severe hepatic or renal impairment, and it is not recommended for pregnant or breastfeeding women unless absolutely necessary.